Autologous Humanized Mouse Model of Non-Small Cell Lung Cancer (NSCLC) to Investigate the Tumor-Immune Landscape and Its Response to Treatment

非小细胞肺癌 (NSCLC) 自体人源化小鼠模型，用于研究肿瘤免疫景观及其对治疗的反应

• 批准号: 10472627
• 负责人: Michael Chiorazzi
• 金额: $ 14.82万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-17 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10472627
• 关键词: Active Immunotherapy; Address; Allogenic; Animal Model; Antibody Therapy; Antineoplastic Agents; Aspirate substance; Autologous; B-Lymphocytes; Biological Products; Biopsy; Blood; Bone Marrow; Cancer Etiology; Cancer Patient; Cells; Clinical; Clinical Trials; Complex; Data; Development; Doctor of Philosophy; Drug usage; Engraftment; Exhibits; Failure; Flow Cytometry; Functional disorder; Gene Expression Profile; Genetic; Genetic Transcription; Genomic approach; Genomics; Goals; Growth; Growth Factor; Harvest; Hematopoietic; Hematopoietic Neoplasms; Hematopoietic System; Hematopoietic stem cells; Human; Immune; Immune System Diseases; Immune system; Immunofluorescence Immunologic; Immunooncology; Immunosuppression; Immunotherapeutic agent; Immunotherapy; Individual; Innate Immune System; Institutional Review Boards; Intervention; Knowledge; Light; Location; Manuscripts; Medical Oncology; Mentorship; Methods; Minority; Modeling; Mus; Myeloid Cells; Natural Killer Cells; Non-Small-Cell Lung Carcinoma; Operative Surgical Procedures; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Physicians; Physiological; Population; Postdoctoral Fellow; Pre-Clinical Model; Preparation; Principal Investigator; Proteomics; Protocols documentation; Research; Research Personnel; Role; Sampling; Scientist; System; T-Lymphocyte; Time; Tissues; Training; Treatment Failure; Tumor Promotion; Tumor-associated macrophages; Tumor-infiltrating immune cells; Vascular Endothelial Growth Factors; anti-PD-L1; bevacizumab; career; drug action; drug efficacy; exhaust; exhaustion; genomic data; humanized mouse; improved; improved outcome; individual patient; macrophage; melanoma; mortality; mouse development; mouse model; neoplastic cell; patient derived xenograft model; patient response; pembrolizumab; peripheral blood; receptor; response; single cell analysis; treatment response; tumor; tumor growth; tumor microenvironment; tumor-immune system interactions

PROJECT SUMMARY Non-small cell lung cancer (NSCLC) remains the major cause of cancer mortality across the globe, despite exciting advances in immune-based therapies. These therapies, while dramatically effective in some patients, are ineffective in the majority of NSCLC patients. The causes of treatment failure remain incompletely understood, as is the role of the local tumor microenvironment (TME) in influencing tumor growth, both in the presence and absence of these therapies. To better study human tumor-immune interactions and immunotherapeutics, we have developed a humanized mouse model that supports the engraftment of mice bearing a matched human hematopoietic system and tumor from an individual NSCLC patient. In addition, this model is unique in its support of functional myeloid cells as part of the innate immune system. We propose to use these autologously-engrafted humanized NSCLC PDX models to study the TME in detail, employing flow cytometric, immunostaining and single cell genomic analyses to characterize the transcriptional and proteomic states of the cells present. We will correlate tumor growth to specific cell populations identified with these methods, enhancing our understanding of the pathways active in tumor- vs blood-resident immune cells, and identifying established and possibly new networks of immune dysfunction in the TME. Armed with this knowledge, we will probe the pathways active in these patient models using drugs specific to the immune exhaustion and tumor promoting mechanisms we identify. Our goal is to gain a deeper understanding of how the TME and immunotherapeutics interact, and to develop these immune avatar mice as models that may predict a patient’s response to a particular immunotherapy. The principal investigator is a physician-scientist, with a PhD in genetics and post-doctoral and clinical training in Medical Oncology. His career goal is to become an independent investigator studying tumor-immune interactions. The proposed K08 training plan will provide the candidate with mentorship and coursework to build the expertise necessary to execute the proposed project and become independent in the field of translational immuno-oncology.

项目总结